Ginkgo Bioworks Holdings Inc. (DNA)
DNA trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$11.76
-0.25% on the day
Market cap
$756.6M
Small cap
Revenue · 2025
$170.2M
-25.1% on 2024
Net income · 2025
-$313K
-0.2% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | DNA on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001830214 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $170.2M |
| Net income | -$313K |
| Operating income | -$315.3M |
| Net margin | -0.2% |
| Operating margin | -185.3% |
| Revenue growth | -25.1% |
| Cash | $167.2M |
| Total assets | $1.1B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-09-04 |
| Latest annual report | 10-K | 2026-02-26 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-08-05 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +0.3% |
| 1 month | +64.7% |
| 3 months | +38.8% |
| Year to date | +38.5% |
| 1 year | -12.5% |
| From 52-week high | -27.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SANA | Sana Biotechnology Inc. | $2.41 | -8.02% | $721.5M |
| CADL | Candel Therapeutics Inc. | $9.27 | -5.21% | $709.3M |
| ODTX | Odyssey Therapeutics Inc. | $17.24 | -5.59% | $828.5M |
| FDMT | 4D Molecular Therapeutics Inc. | $12.36 | -4.92% | $682.8M |
| GLUE | Monte Rosa Therapeutics Inc. | $9.89 | -5.99% | $843.7M |
| ATTO | Attovia Therapeutics Inc. | $14.72 | +0.89% | $672.0M |
| SLBT | SL Science Holding Limited | $1.53 | +1.32% | $858.0M |
| AURA | Aura Biosciences Inc. | $6.27 | -4.13% | $650.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier